Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma

Código QR

Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma

Abstract The aim of this study was to identify the relationships of epidermal growth factor receptor (EGFR) mutations and anaplastic large-cell lymphoma kinase (ALK) status with CT characteristics in adenocarcinoma using the largest patient cohort to date. In this study, preoperative chest CT findin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaoyu Han, Jun Fan, Yumin Li, Yukun Cao, Jin Gu, Xi Jia, Yuhui Wang, Heshui Shi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/bfbca12fd1d94d028d0094be93f511ee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
por: Svetlana V. Odintsova, et al.
Publicado: (2020)

Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas
por: Daisuke Akahori, et al.
Publicado: (2021)

TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations
por: Ouseph MM, et al.
Publicado: (2019)

Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
por: Jeng-Sen Tseng, et al.
Publicado: (2014)

Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique
por: Yangchun Gu, et al.
Publicado: (2021)

Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers
por: Pauline Gilson, et al.
Publicado: (2021)

Prognostic Value of CT Radiomic Features in Resectable Pancreatic Ductal Adenocarcinoma
por: Farzad Khalvati, et al.
Publicado: (2019)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma
por: Kouya Shiraishi, et al.
Publicado: (2016)

Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma
por: Jiang WT, et al.
Publicado: (2018)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng L, et al.
Publicado: (2018)

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
por: Huan Zhang, et al.
Publicado: (2021)

Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo
por: Xiangxiang Hu, et al.
Publicado: (2017)

ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells
por: Anna M. Schläfli, et al.
Publicado: (2021)

Antiangiogenic therapy in pretreated patients with lung adenocarcinoma without activating mutations: new features
por: Elena V. Reutova, et al.
Publicado: (2021)

Predictive values of multiple non-invasive markers for myocardial fibrosis in hypertrophic cardiomyopathy patients with preserved ejection fraction
por: Yumin Li, et al.
Publicado: (2021)

Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel”
por: Umberto Caterino, et al.
Publicado: (2021)

First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi S, et al.
Publicado: (2015)

Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
por: Yukari Tsubata, et al.
Publicado: (2021)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Xiaoying Zhang
Publicado: (2021)

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
por: Zhu VW, et al.
Publicado: (2018)

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
por: Suda K, et al.
Publicado: (2013)

Effect of brain radiotherapy strategies on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis
por: Guangchuan Deng, et al.
Publicado: (2021)

Identification of Six Prognostic Genes in EGFR–Mutant Lung Adenocarcinoma Using Structure Network Algorithms
por: Haomin Zhang, et al.
Publicado: (2021)

Circulating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers.
por: Huan Zhang, et al.
Publicado: (2013)

Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing
por: Rahul Nahar, et al.
Publicado: (2018)

EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers?
por: Wang QS, et al.
Publicado: (2013)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
por: Ken Uchibori, et al.
Publicado: (2017)

A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
por: Igawa S, et al.
Publicado: (2021)

Clinical and surgical implications of EGFR mutations in non-small cell lung cancer
por: M. Yoon, et al.
Publicado: (2016)

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
por: Shuluan Li, et al.
Publicado: (2021)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
por: Caiyu Lin, et al.
Publicado: (2021)

Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients.
por: Pablo Martinez, et al.
Publicado: (2013)

Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study
por: Xinqing Lin, et al.
Publicado: (2021)

Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma
por: Zhang Shi, et al.
Publicado: (2017)

Adenocarcinoma in situ and minimally invasive adenocarcinoma in lungs of smokers: image feature differences from those in lungs of non-smokers
por: Haruto Sugawara, et al.
Publicado: (2021)

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
por: Tereza Vaclova, et al.
Publicado: (2021)

Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
por: Shang-Gin Wu, et al.
Publicado: (2011)

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
por: Lei Wang, et al.
Publicado: (2014)